A well-tolerated milk protein studied in cancer for decades. Human evidence is thin and mixed: it may slow precancerous growths in the bowel and ease chemotherapy-related taste changes, but has not been shown to treat established cancer. Best viewed as a low-risk option for prevention and supportive care, not treatment. (Full Review)

Protocol

Dose

250 mg – 3 g/day

Oral bovine lactoferrin; start low and titrate up as tolerated

Timing

Split 2–3× daily

With food; separate from iron supplements

Formulation

Apo (iron-free), enteric-coated

Preferred to survive stomach acid and maximize iron-binding

Time to effect

Polyp suppression

~12 months

Prevention endpoint judged over months, not days

Immune activation

Within weeks

Immune-marker changes appear early

Benefits

Medium: Slowed growth of precancerous colorectal polyps

Low: Enhanced antitumor immune surveillance; reduced chemotherapy-induced taste disturbance; direct tumor-cell apoptosis and growth arrest; inhibited angiogenesis and metastasis

Speculative: Sensitization to chemotherapy and radiotherapy; iron sequestration and ferroptosis modulation

Contraindications

Cow's-milk allergy

Iron-overload disorders (e.g., hereditary hemochromatosis)

Pregnancy and lactation

Key Interactions

Oral iron supplements (ferrous sulfate, ferrous fumarate)

Tetracycline-class antibiotics (doxycycline, minocycline)

Mineral supplements (calcium, zinc)

Chemotherapy

Risk & Side Effects

High: Gastrointestinal discomfort

Medium: Milk allergy and hypersensitivity reactions; iron-status and absorption interactions

Low: Context-dependent tumor-promoting signaling; minor systemic effects

Speculative: Long-term high-dose iron-modulation effects

Monitoring

Marker	Target	Why
Ferritin	~30–100 ng/mL	Reflects iron stores; guards against iron overload and deficiency
Transferrin saturation	~25–35%	Indicates iron availability; a rising value flags overload risk
hs-CRP	< 1.0 mg/L	Tracks systemic inflammation, a target of lactoferrin's proposed action
Complete blood count	Within age/sex reference	Screens for anemia and general blood health
Serum iron	~60–150 µg/dL	Complements transferrin saturation in assessing iron balance

Cadence: Baseline, then every 6–12 months; every 3–6 months with iron-overload risk or during cancer treatment

Qualitative Assessment

Gastrointestinal comfort — no new nausea, constipation, or diarrhea
Energy levels — stable or improved daily energy, without new fatigue
Infection frequency — fewer or milder minor infections
Taste and appetite during chemotherapy — improved taste perception and appetite

Lactoferrin to Treat Cancer

Protocol

Benefits

Risk & Side Effects

Monitoring

Qualitative Assessment